Pritor/Kinzal-Exceeding the ARB promise
Malta, 23 September 2006
The Bayer HealthCare Symposium 'Pritor/Kinzal-Exceeding the ARB promise', which outlined how Pritor/Kinzal can address the current challenges in hypertension management, delivered a very comprehensive programme to more than 600 physicians from across Europe. The eminent faculty agreed that Pritor/Kinzal not only provides effective and sustained blood pressure control, but has additional cardiometabolic advantages
The symposium dealt with a wide range of topics, including the future of hypertension management, the importance of managing risk factors, reasons for suboptimal blood pressure control, head-to-head comparisons of Pritor/Kinzal with other ARBS and other drug classes and controlling hypertension as part of a multiple-risk-factor management strategy.
Download Meeting Summary
Download Abstract Booklet
Download Meeting Programme
Picture Gallery
The Bayer HealthCare Symposium 'Pritor/Kinzal-Exceeding the ARB promise', which outlined how Pritor/Kinzal can address the current challenges in hypertension management, delivered a very comprehensive programme to more than 600 physicians from across Europe. The eminent faculty agreed that Pritor/Kinzal not only provides effective and sustained blood pressure control, but has additional cardiometabolic advantages
The symposium dealt with a wide range of topics, including the future of hypertension management, the importance of managing risk factors, reasons for suboptimal blood pressure control, head-to-head comparisons of Pritor/Kinzal with other ARBS and other drug classes and controlling hypertension as part of a multiple-risk-factor management strategy.
Download Meeting Summary
Download Abstract Booklet
Download Meeting Programme
Picture Gallery
